Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MAGEA1 is a member of the MAGEA gene family. Additionally we are shipping Melanoma Antigen Family A, 1 (Directs Expression of Antigen MZ2-E) Kits (16) and Melanoma Antigen Family A, 1 (Directs Expression of Antigen MZ2-E) Proteins (10) and many more products for this protein.
Showing 10 out of 117 products:
Human Polyclonal MAGEA1 Primary Antibody for EIA, IHC (p) - ABIN358644
Suyama, Ohashi, Nagai, Hatano, Asano, Murate, Saito, Kinoshita: The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies. in Leukemia research 2002
Show all 5 references for ABIN358644
Human Polyclonal MAGEA1 Primary Antibody for WB - ABIN2782493
Ries, Vairaktaris, Mollaoglu, Wiltfang, Neukam, Nkenke: Expression of melanoma-associated antigens in oral squamous cell carcinoma. in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2008
Human Polyclonal MAGEA1 Primary Antibody for IHC (p), WB - ABIN390105
Celis, Fikes, Wentworth, Sidney, Southwood, Maewal, Del Guercio, Sette, Livingston: Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. in Molecular immunology 1995
The overall survival of laryngeal squamous cell carcinoma patients with positive MAGE-A1, MAGE-A9, or MAGE-A11 expression was lower than the patients without MAGE-A1, MAGE-A9, or MAGE-A11 expression.
MAGE (show MAGEB10 Antibodies)-A is more highly expressed than NY-ESO-1 (show CTAG1B Antibodies) in a majority of human malignancies
TRIM31 (show TRIM31 Antibodies) directly binds to NSE4, suggesting the existence of a TRIM31 (show TRIM31 Antibodies)-MAGEA1-NSE4 complex reminiscent of the NSE1 (show FAM84A Antibodies)-NSE3 (show NDNL2 Antibodies)-NSE4 trimer.
Results suggest that MAGE-D4 (show MAGED4 Antibodies) overexpression influences tumor progression, and MADE-D4 can be a prognostic marker and a potential molecular target in squamous cell esophageal cancer.
Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.
These findings suggest MAGE-D4 (show MAGED4 Antibodies) may serve as a potentially prognostic biomarker and an attractive target of immunotherapy in colorectal cancer
MAGE-D4 (show MAGED4 Antibodies) is highly expressed in glioma and can develop specifically humoral response in glioma patients.
MAGED4 (show MAGED4 Antibodies) (mRNA and protein) is frequently and highly expressed in glioma and is partly regulated by DNA methylation (show HELLS Antibodies).
DNA methylation (show HELLS Antibodies) has a dominant role in the epigenetic hierarchy governing MAGEA1 expression
results show the absence and/or low expression of MAGE (show MAGEB10 Antibodies) A1 transcripts in oral squamous cell carcinoma; presence of hypomethylation at a small level at the promoter site of MAGE (show MAGEB10 Antibodies) A1 was detected in both oral squamous cell carcinoma and normal oral mucosa
May enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex.
, antigen MZ2-E
, cancer/testis antigen 1.1
, cancer/testis antigen family 1, member 1
, melanoma antigen MAGE-1
, melanoma antigen family A 1
, melanoma-associated antigen 1
, melanoma-associated antigen MZ2-E
, MAGE-D4 antigen
, MAGE-E1 antigen
, melanoma-associated antigen D4